generation run 2026-05-11
57 min completedmodel pipeline-v5plan not recordedrun/18af9fc6…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
6 further caveats recorded as free text — readable on the working page
Reproduce
- inputs
- 19 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
25 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | PubMed | methylethyltryptamine serotonin receptor psychedelic | 15 | 2 | Selected pharmacologically relevant tryptamine papers; discarded unrelated results |
| 2 | ClinicalTrials.gov · absence | methylethyltryptamine MET tryptamine | 0 | — | — |
| 3 | PubMed | MET N-methyl-N-ethyltryptamine pharmacology | 15 | — | — |
| 4 | PubChem | N-methyl-N-ethyltryptamine | 1 | 1 | Primary chemical identity verification |
| 5 | PubMed | tramadol serotonin syndrome interaction risk serotonergic drugs | 8 | 2 | — |
| 6 | OpenAlex | N-methyl-N-ethyltryptamine MET psychedelic tryptamine | 15 | 5 | High-citation relevant papers on tryptamine pharmacology and toxicology |
| 7 | PsychonautWiki | — | 1 | — | — |
| 8 | WebSearch | MET methylethyltryptamine N-methyl-N-ethyltryptamine legal status scheduling DEA | 10 | 3 | Legal status information not available via academic APIs |
| 9 | Erowid | — | 1 | — | — |
| 10 | WebSearch | TiHKAL Shulgin MET methylethyltryptamine tryptamine synthesis history | 10 | 2 | Historical/discovery information not in academic databases |
| 11 | PubMed | N-methyl-N-ethyltryptamine tryptamine analog | 15 | — | Discarded as irrelevant to MET |
| 12 | PubMed | Glennon tryptamine serotonin receptor structure activity binding affinity psychedelic | 5 | 3 | Classic SAR papers establishing how N-substitution patterns affect 5-HT2A binding; directly relevant to MET vs DMT comparison |
| 13 | PubChem REST API | CID 824845 chemical properties | 1 | 3 | Chemical identity data missing from seed brief |
| 14 | ClinicalTrials.gov · absence | methylethyltryptamine MET tryptamine | 0 | — | — |
| 15 | PubMed | tramadol serotonin syndrome interaction risk serotonergic drugs | 8 | 2 | Relevant to MET interactions section (tramadol + serotonergic agent = SS risk) |
| 16 | PubMed · absence | psychedelic serotonergic cross-tolerance 5-HT2A receptor downregulation tachyphylaxis LSD psilocybin | 0 | — | — |
| 17 | WebSearch | MET methylethyltryptamine UK Psychoactive Substances Act Germany scheduling Australia | 10 | 4 | Legal status not in academic databases |
| 18 | Erowid TiHKAL online | MET methylethyltryptamine TiHKAL entry | 1 | 2 | Primary historical source for MET description |
| 19 | Crossref DOI verification | DOI verification for Luethi 2020, Warren 2024, Tittarelli 2015 | 3 | — | — |
| 20 | WebSearch | MET methylethyltryptamine TiHKAL entry description effects Shulgin 1997 | 10 | — | — |
| 21 | Multiple sources synthesis | MET legal status all jurisdictions | 5 | — | — |
| 22 | PubChem REST API + OpenAlex cross-reference | MET chemical identity SMILES InChI CID 824845 | 1 | — | — |
| 23 | PsychonautWiki | MET methylethyltryptamine pharmacology effects dosage duration | 1 | — | — |
| 24 | OpenAlex | Shulgin tryptamine structure activity relationship N-substituted analogs psychedelic | 10 | — | — |
| 25 | Seed data vs published sources | MET oral dose comparison Shulgin vs community consensus | 2 | — | — |
42 claims by section — every cited sentence, checked against its source
safety15 · 6 ok
Claim in safety — inconclusiveinconclusiveworking →
A 2015 forensic case report detected 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET, a 4-hydroxyl-substituted structural analog) in postmortem biological samples; cause of death was certified as acute mixed drug intoxication primarily attributed to 4-methoxyphencyclidine (4-MeO-PCP), with co-medications including venlafaxine, olanzapine, lorazepam, and hydroxyzine at therapeutic levelssupported
Postmortem case: 4-MeO-PCP principal cause of death; 4-HO-MET detected by GC-MS (not quantified); co-medications at therapeutic levels. bkv089
The serotonergic psychedelic class generally shows low 5-HT₂B receptor activation at typical doses, corresponding to reduced cardiac valvulopathy risk with intermittent usesupported
Low 5-HT2B activation suggests reduced cardiac risk. j.euroneuro.2026.112835
Confirmatory identification requires GC-MS or LC-MS/MS.supported
LC-MS/MS method for 56 NPS including tryptamines in blood and urine. bio.15.48
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Combination with any agent that increases synaptic serotonin concentration or directly activates serotonin receptors carries risk of serotonin toxicity (serotonin syndrome).supported
Review of drug-drug interaction and serotonin toxicity risk between serotonergic psychedelics and standard psychiatric medications including SSRIs. s00213-021-05876-x
This combination is classified as dangerous.supported
Review of drug-drug interaction and serotonin toxicity risk between serotonergic psychedelics and standard psychiatric medications. s00213-021-05876-x
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
SSRIs and SNRIs are documented to blunt psychedelic effects via chronic 5-HT₂A receptor downregulation while carrying theoretical serotonin toxicity risk in acute combination.supported
Review of drug-drug interaction and serotonin toxicity risk between serotonergic psychedelics and standard psychiatric medications including SSRIs. s00213-021-05876-x
Claim in safety — inconclusiveinconclusiveworking →
receptor-pharmacology10 · 9 ok
The 5-HT₂A receptor is the primary mediator of psychedelic effects for all classical hallucinogenic tryptaminessupported
Classical hallucinogens possess 5-HT2 agonist activity; discriminative stimulus potency correlates with 5-HT2 receptor affinity. pmid:1435968
Binding affinity at 5-HT₂ receptors follows a structure-activity gradient across N,N-dialkyltryptamines: progressive increase in N-alkyl bulk decreases affinitysupported
Terminal amine methylation: primary amine > dimethylamine > diethylamine affinity. pmid:3350047
Claim in receptor-pharmacology — inconclusiveinconclusiveworking →
PLC–IP₁ formation via Gq/11 is the pathway most strongly correlated with human psychoactive potency; PLA₂–arachidonic acid and β-arrestin2 recruitment also occur with compound-specific bias.supported
IP1 formation best correlates with human psychoactive doses. Characterized signaling at 5-HT2A via PLC-IP1, PLA2, beta-arrestin2, Gi. j.euroneuro.2026.112835
Serotonergic tryptamines with N,N-dialkyl substitution engage 5-HT₁A receptors as partial agonistssupported
Cryo-EM structures of 5-HT1A with 5-MeO-DMT and analogues. SAR of 5-methoxytryptamines at 5-HT1A and 5-HT2A. s41586-024-07403-2
Serotonergic tryptamines with N,N-dialkyl substitution engage 5-HT₁A receptors as partial agonistssupported
Receptor binding profiles of tryptamine-based psychedelics; multiple serotonin receptors including 5-HT1A. acsptsci.2c00222
The 5-HT₁A component attenuates the 5-HT₂A-mediated head-twitch response and modulates thermoregulation, anxiety, and overall psychedelic intensitysupported
HTR mediated primarily by 5-HT2A; all tested tryptamines showed selectivity for 5-HT1AR over 5-HT2AR; insights into psychoactive and thermoregulatory properties. s41380-024-02506-8
The 5-HT₁A component attenuates the 5-HT₂A-mediated head-twitch response and modulates thermoregulation, anxiety, and overall psychedelic intensitysupported
5-HT1A receptors modulate 5-HT2A-mediated behavioral effects (HTR) of 5-MeO-DMT analogs in mice. 5-HT1A agonism attenuates psychedelic behavioral signature. acschemneuro.4c00513
Serotonergic psychedelics as a class show low 5-HT₂B receptor activation at typical doses, corresponding to reduced cardiac valvulopathy risk with intermittent usesupported
Low 5-HT2B activation suggests reduced cardiac risk. j.euroneuro.2026.112835
Psychedelic tryptamines interact with a range of serotonin receptor subtypes (5-HT₂C, 5-HT₆, 5-HT₇) and may show weak affinity at sigma, TAAR1, and other aminergic receptorssupported
Receptor affinity pharmacology of 25 psychedelic drugs at 51 receptors, transporters, and ion channels via NIMH-PDSP. journal.pone.0009019
pharmacology9 · 7 ok
Classical hallucinogenic tryptamines exert psychedelic effects primarily through agonism at the serotonin 5-HT₂A receptorsupported
Classical hallucinogens possess 5-HT2 agonist activity; hallucinogens may be high-affinity 5-HT2 partial agonists; discriminative stimulus potency correlates with 5-HT2 receptor affinity. pmid:1435968
At the signaling level, phospholipase C–inositol monophosphate (PLC–IP₁) formation via Gq/11 coupling is the readout most strongly correlated with human psychoactive doses across serotonergic psychedelics; compounds also activate phospholipase A₂–arachidonic acid and β-arrestin2 pathways at 5-HT₂A, with compound-specific bias profiles influencing experiential character.supported
IP1 formation best correlates with human psychoactive doses. 5-HT2A/5-HT1A ratio informs seizure risk. Characterized signaling of serotonergic psychedelics at 5-HT2A, 5-HT2B, 5-HT2C, 5-HT1A via PLC-IP1, PLA2, beta-arrestin2, Gi. j.euroneuro.2026.112835
Structure-activity data across 21 indolealkylamines at rat brain 5-HT₂ receptors, measured via [³H]ketanserin displacement, established a clear affinity gradient: terminal amine primary amine > N,N-dimethyl (DMT-class) > N,N-diethyl (DET-class)supported
SAR for 21 indolealkylamines at 5-HT2 receptors. Terminal amine methylation: primary amine > dimethylamine > diethylamine affinity. pmid:3350047
Secondary engagement of 5-HT₁A receptors as a partial agonist is well-documented across N,N-dialkylated tryptaminessupported
Cryo-EM structures of 5-HT1A with 5-MeO-DMT and analogues. SAR of 5-methoxytryptamines at 5-HT1A and 5-HT2A. s41586-024-07403-2
Secondary engagement of 5-HT₁A receptors as a partial agonist is well-documented across N,N-dialkylated tryptaminessupported
Receptor binding profiles of tryptamine-based psychedelics; multiple serotonin receptors including 5-HT1A. acsptsci.2c00222
The 5-HT₁A component modulates phenomenological character, generally attenuating head-twitch response (HTR), reducing psychedelic intensity, and contributing anxiolytic and thermoregulatory effectssupported
HTR mediated primarily by 5-HT2A; all tested tryptamines showed selectivity for 5-HT1AR over 5-HT2AR; N-group size influences SERT affinity. s41380-024-02506-8
The ratio of 5-HT₂A to 5-HT₁A activation may also inform seizure risk.supported
5-HT2A/5-HT1A ratio informs seizure risk. j.euroneuro.2026.112835
Claim in pharmacology — inconclusiveinconclusiveworking →
Claim in pharmacology — inconclusiveinconclusiveworking →
summary3 · 1 ok
As a substituted tryptamine, MET is presumed to act primarily through agonism at the serotonin 5-HT₂A receptor and partial agonism at 5-HT₁A, consistent with the classical psychedelic mechanismsupported
Classical hallucinogens possess 5-HT2 agonist activity; hallucinogens may be high-affinity 5-HT2 partial agonists; discriminative stimulus potency correlates with 5-HT2 receptor affinity. pmid:1435968
Claim in summary — inconclusiveinconclusiveworking →
Claim in summary — inconclusiveinconclusiveworking →
pharmacokinetic-detail2 · 0 ok
chemistry1 · 1 ok
Structure-activity relationship studies across indolealkylamines demonstrate that increasing N-alkyl bulk progressively reduces 5-HT₂ receptor binding affinity: primary amine > N,N-dimethyl > N,N-diethylsupported
SAR for 21 indolealkylamines at 5-HT2 receptors. Terminal amine methylation: primary amine > dimethylamine > diethylamine affinity. pmid:3350047
comparative-pharmacology1 · 1 ok
5-HT₂A affinity: DMT > MET > DET, based on the inverse relationship between N-alkyl bulk and receptor binding.supported
Terminal amine methylation: primary amine > dimethylamine > diethylamine affinity. pmid:3350047
neuroscience1 · 1 ok
As a presumed 5-HT₂A agonist, MET is expected to engage the same neural systems characterized in studies of psilocybin, LSD, and DMTsupported
Classical hallucinogens possess 5-HT2 agonist activity; discriminative stimulus potency correlates with 5-HT2 receptor affinity. pmid:1435968